Prednisone Terminated Phase 2 Trials for Prostate Cancer Treatment

TerminatedTreatment2 IdentifierTitleDrugs
NCT00385827A Safety and Efficacy Study of Siltuximab (CNTO 328) in Male Subjects With Metastatic Hormone-Refractory Prostate Cancer (HRPC)
NCT01994590Dovitinib (TKI258) and Abiraterone Acetate in Metastatic Castrate-Resistant Prostate Cancer (mCRPC)
NCT00348816Docetaxel, Radiation Therapy, and Prednisone in Treating Patients Who Have Undergone Surgery For Prostate Cancer